Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replication

Journal of Medicinal Chemistry

Volumn 54, Issue 12, 2011, Pages 4119-4132

  Stachulski, Andrew V ^a,b   Pidathala, Chandrakala ^a   Row, Eleanor C ^a   Sharma, Raman ^a   Berry, Neil G ^a   Iqbal, Mazhar ^a   Bentley, Joanne ^a   Allman, Sarah A ^b   Edwards, Geoffrey ^a   Helm, Alison ^a   Hellier, Jennifer ^a   Korba, Brent E ^c   Semple, J Edward ^d   Rossignol, Jean Francois ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^d Romark Institute for Medical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXY 3 METHYLBENZOYL N (4 PHENYLTHIAZOL 2 YL)AMIDE; 2 HYDROXY 3 METHYLBENZOYL N (5 BROMOTHIAZOL 2 YL)AMIDE; 2 HYDROXY 5 METHYLBENZOYL N (5 CHLOROTHIAZOL 2 YL)AMIDE; 2 HYDROXYBENZOYL N (5 ACETAMIDOTHIAZOL 2 YL)AMIDE; 2 HYDROXYBENZOYL N (5 CHLOROTHIAZOL 2 YL)AMIDE; 3 CHLORO 2 HYDROXYBENZOYL N (5 BROMOTHIAZOL 2 YL)AMIDE; ANTIVIRUS AGENT; ETHYL 2 [(5 NITRO 1,3 THIAZOL 2 YL)CARBAMOYL]PHENYLCARBONATE; NITAZOXANIDE; PLASMA PROTEIN; SALICYLOYLANILIDE; THIAZOLIDE DERIVATIVE; TIZOXANIDE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SYNTHESIS; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; VIRION; VIRUS REPLICATION;

AMIDES; ANIMALS; ANTIVIRAL AGENTS; DOGS; GLUCURONIDES; HEP G2 CELLS; HEPATITIS B VIRUS; HUMANS; PRODRUGS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS; SALICYLAMIDES; THIAZOLES; VIRION; VIRUS REPLICATION;

EID: 79959448653     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200153p     Document Type: Article

References (80)

1. Chen, D. S. Hepatitis B vaccination: the key towards elimination and eradication of hepatitis B J. Hepatol. 2009, 50, 805-816
2. Dane, D. S.; Cameron, C. H.; Briggs, M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis Lancet 1970, 695-698
3. Summers, J.; OConnell, A.; Millman, I. Genome of hepatitis B virus: restriction enzyme cleavage and structure of DNA extracted from Dane particles Proc. Natl. Acad. Sci. U.S.A. 1975, 72, 4597-4601
4. Blumberg, B. S. Australia antigen and the biology of hepatitis B Science 1977, 197, 17-25 (Pubitemid 8128337)
5. Poland, G. A. Evaluating existing recommendations for hepatitis A and B vaccination Am. J. Med. 2005, 118 (10A) 16S-20S (Pubitemid 41552427)
6. Ni, Y. H.; Chang, M. H.; Huang, L. M.; Chen, H. L.; Hsu, H. Y.; Chiu, T. Y.; Tsai, K. S.; Chen, D. S. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination Ann. Intern. Med. 2001, 135, 796-800
7. Kohlstaedt, L. A.; Wang, J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Crystal structure at 3.5A resolution of HIV reverse transcriptase complexed with an inhibitor Science 1992, 256, 1783-1790
8. Doong, S.-L.; Tsai, C.-H.; Schinazi, R.-F.; Liotta, D. C.; Cheng, Y.-C. Inhibition of the replication of hepatitis B virus in vitro by 2′, 3′-dideoxy-3′-thiacytidine and related analogues Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 8495-8499 (Pubitemid 21915383)
9. Lok, A. S.; Lai, C. L.; Leung, N.; Yao, G. B.; Cui, Z. Y.; Schiff, E. R.; Fienstag, J. L.; Heathcote, E. J.; Little, N. R.; Griffiths, D. A.; Gardner, S. D.; Castiglia, M. Long-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 2003, 125, 1714-1722 (Pubitemid 37500436)
10. Yang, H.; Westland, C. E.; Delaney, W. E. T.; Heathcote, E. J.; Ho, V.; Fry, J.; Brosgart, C.; Gibbs, C. S.; Miller, M. D.; Xiong, S. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks Hepatology 2002, 36, 464-473 (Pubitemid 34810368)
11. Warner, N.; Locarnini, S. A.; Colledge, D.; Edwards, R.; Angus, P.; Sievert, W.; Kuiper, M.; Chalmers, D.; Bartholomeusz, A. Molecular modeling of entecavir resistant mutations in the hepatitis B virus polymerase selected during therapy Hepatology 2003, 40, 245A
12. Ghany, M.; Liang, T. J. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B Gastroenterology 2007, 132, 1574-1585 (Pubitemid 46627588)
13. Weber, O.; Schlemmer, K. H.; Hartmann, E.; Hagelschuer, I.; Paessens, A.; Graef, E.; Deres, K.; Goldman, S.; Niewoehner, U.; Stoltefuss, J.; Haebich, D.; Ruebsamen-Waigmann, H.; Wohlfeil, S. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model Antiviral Res. 2002, 54, 69-78 (Pubitemid 34327685)
14. King, R. W.; Ladner, S. K.; Miler, T. J.; Zaifert, K.; Perni, R. B.; Conway, S. C.; Otto, M. J. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)β-L-2′,3′-dideoxy-3′-thiacytidine Antimicrob. Agents Chemother. 1998, 42, 3179-3186 (Pubitemid 28553739)
15. Dwek, R. A.; Butters, T. D.; Platt, F. M.; Zitzmann, N. Targeting glycosidation as a therapeutic approach Nat. Rev. Drug Discovery 2002, 1, 65-75
16. Mehta, A.; Zitzmann, N.; Rudd, P. M.; Block, T. M.; Dwek, R. A. Alpha-glucosidase inhibitors as potential broad based anti-viral agents FEBS Lett. 1998, 430, 17-22 (Pubitemid 28307024)
17. Block, T. M.; Lu, X.; Mehta, A. S.; Blumberg, B. S.; Tennant, B.; Ebling, M.; Korba, B. E.; Lansky, D. M.; Jacob, G. S.; Dwek, R. A. Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking Nat. Med. 1998, 4, 610-614 (Pubitemid 28237362)
18. Korba, B. E.; Gerin, J. L. Antisense oligonucleotides are effective inhibitors of hepatitis B virus replication in vitro Antiviral Res. 1995, 28, 225-242
19. Wu, H. L.; Huang, L. R.; Huang, C. C.; Lai, H. L.; Liu, C. J.; Huang, Y. T.; Hsu, Y. W.; Lu, C. Y.; Chen, D. S.; Chen, P. J. RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant Gastroenterology 2005, 128, 708-716
20. Loomba, R.; Liang, T. J. Novel approaches to new therapies for hepatitis B viral infection Antiviral Ther. 2006, 11, 1-15
21. Fox, L. M.; Saravolatz, L. D. Nitazoxanide: a new thiazolide antiparasitic agent Clin. Infect. Dis. 2005, 40, 1173-1180 (Pubitemid 40490245)
22. Gargala, G.; Le Goff, L.; Ballet, J. J.; Favennec, L.; Rossignol, J.-F.; Stachulski, A. V. Evaluation of new thiazolide/thiadiazolide derivatives reveals nitro group-independent efficacy against in vitro development of Cryptosporidium parvum Antimicrob. Agents Chemother. 2010, 54, 1315-1318
23. Dubrueil, L.; Houcke, I.; Mouton, Y.; Rossignol, J.-F. In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms Antimicrob. Agents Chemother. 1996, 40, 2266-2270 (Pubitemid 26328028)
24. Rossignol, J.-F.; Maisonneuve, H. Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana Am. J. Trop. Med. Hyg. 1984, 33, 511-512 (Pubitemid 14075656)
25. Doumbo, O.; Rossignol, J.-F.; Pichard, E.; Traore, H.; Dembele, M.; Diakite, M.; Traore, F.; Diallo, D. A. Nitazoxanide in the treatment of cryptosporidial diahorrea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa Am. J. Trop. Med. Hyg. 1997, 56, 637-639 (Pubitemid 27318586)
26. Rossignol, J.-F. Nitazoxanide in the treatment of acquired immune deficiency syndrome-related cryptosporidiosis: results of the United States compassionate program in 365 patients Aliment. Pharmacol. Ther. 2006, 24, 887-894
27. Hoffmann, P. S.; Sisson, G.; Croxen, M. A.; Welch, K.; Harman, W. D.; Cremades, N.; Morash, M. G. Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductase of Helicobacter pylori and selected anaerobic bacteria and parasites, and Campylobacter jejuni Antimicrob. Agents Chemother. 2007, 51, 868-876 (Pubitemid 46355269)
28. Gargala, G.; Le Goff, L.; Ballet, J. J.; Favennec, L.; Stachulski, A. V.; Rossignol, J.-F. In vitro efficacy of nitro-and halogeno-thiazolide/ thiadiazolide derivatives against Sarcocystis neurona Vet. Parasitol. 2009, 162, 230-235
29. Korba, B. E.; Montero, A. B.; Farrar, K.; Gaye, K.; Mukerjee, S.; Ayers, M. S.; Rossignol, J.-F. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication Antiviral Res. 2008, 77, 56-63
30. Rossignol, J.-F.; Abu-Zekry, M.; Hussein, A.; Santoro, M. G. Effect of nitazoxanide for treatment of severe rotavirus diahorrea: randomized double-blind placebo-controlled trial Lancet 2006, 368, 124-129 (Pubitemid 43994153)
31. Rossignol, J.-F.; El-Gohary, Y. Nitazoxanide in the treatment of viral gastroenteritis: a randomized double-blind, placebo-controlled trial Aliment. Pharmacol. Ther. 2006, 24, 1423-1430 (Pubitemid 44657118)
32. Rossignol, J.-F.; Cavier, R. Chem. Abstr. 1975, 83, 28216
33. Coste, J.; Frérot, E.; Jouin, P. Coupling N-methylated amino acids using PyBroP and PyCloP halogenophosphonium salts: mechanism and fields of application J. Org. Chem. 1994, 59, 2437-2446
34. Tung, R. D.; Rich, D. H. Bis(2-oxo-3-oxazolidinyl)phosphinic chloride as a coupling reagent for N -alkylamino acids J. Am. Chem. Soc. 1985, 107, 4342-4343
35. Carpino, L. A. 1-Hydroxy-7-azabenzotriazole-an effective peptide coupling additive J. Am. Chem. Soc. 1993, 115, 4397-4398
36. Parent, R. A. 2,4-Dinitrothiazole. The boron trifluoride-nitrogen tetroxide nitration of 2-nitrothiazole J. Org. Chem. 1962, 27, 2282-2283
37. Banks, R. E.; Besheesh, M. K.; Mohialdin-Khaffaf, S. N.; Sharif, I. N -Halogeno compounds. Part 18. 1-Alkyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane salts: user-friendly site-selective electrophilic fluorinating agents of the N -fluoroammonium class J. Chem. Soc., Perkin Trans. 1 1996, 2069-2076 (Pubitemid 126801339)
38. Briner, P. H.; Fyfe, M. C. T.; Martin, P.; Murray, P. J.; Naud, F.; Procter, M. J. Practical synthesis of 2-amino-5-fluorothiazole hydrochloride Org. Process Res. Dev. 2006, 10, 346-348 (Pubitemid 43508449)
39. Our results should be compared with the following: Dahlbom, R.; Ekstrand, T. Sulfides and sulfones containing an aminothiazole group Sven. Kem. Tidskrift 1945, 57, 229-234, where it was claimed that a similar displacement of an aminothiazole 5-halide by an aryl sulfinate Na salt gave the 5-sulfone
40. Yamazaki, T.; Ishikawa, N. Building-blocks for trifluoromethylated organic molecules. 2. (E)-3,3,3-Trifluoro-1-propenyl phenyl sulfoxide - a useful building block for trifluoromethylated organic molecules Chem. Lett. 1985, 889
41. Laduron, F.; Janousek, Z.; Viehe, H. G. α- or β- Trifluoromethyl epoxysulfones: new C3 reagents for heterocyclisation J. Fluorine Chem. 1995, 73, 83-86
42. Stachulski, A. V.; Rossignol, J.-F. Syntheses and antibacterial activities of tizoxanide, an N -(nitrothiazolyl)salicylamide, and its O -aryl glucuronide J. Chem. Res. 1999, 44-45
43. Stanford, D.; Stachulski, A. V. Convenient syntheses of deoxypyranose sugars from glucuronolactone Tetrahedron Lett. 2007, 48, 2361-2364 and references therein.
44. Korba, B. E.; Gerin, J. L. Use of a standardized cell culture assay to determine activities of nucleoside analogues against hepatitis B virus replication Antiviral Res. 1992, 19, 55-70
45. Esposito, M.; Stettler, R.; Moores, S. L.; Pidathala, C.; Muller, N.; Berry, N. G.; Stachulski, A. V.; Rossignol, J.-F.; Hemphill, A. In vitro efficacy of nitazoxanide and other thiazolides against Neospora caninum tachyzoites reveals anti-parasitic activity independent of the nitro group Antimicrob. Agents Chemother. 2005, 49, 3715
46. Baillie, T. A. Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism Chem. Res. Toxicol. 2008, 21, 129-137 (Pubitemid 351219714)
47. Matyk, J.; Waisser, K.; Drazkova, K.; Kunes, J.; Klimesova, V.; Palat, K., Jr.; Kaustova, J. Heterocyclic isosteres of antimycobacterial salicylamides Farmaco 2005, 60, 399-408
48. Luo, Q.-L.; Li, J.-Y.; Liu, Z.-Y.; Chen, L.-L.; Li, J.; Ye, Q.-Z.; Nan, F.-J. Inhibitors of type I MetAPs containing pyridine-2-carboxylic acid thiazol-2-yl amide. Part I: SAR studies on the determination of the key scaffold Bioorg. Med. Chem. Lett. 2005, 15, 635-638 (Pubitemid 40143138)
49. Dymicky, M.; Huhtanen, C. N.; Wasserman, A. E. Inhibition of clostridium botulinum by 5-nitrothiazoles Antimicrob. Agents Chemother. 1977, 12, 353-356
50. Waisser, K.; Hladuvkova, J.; Kunes, J.; Kubicova, L.; Klimesova, V.; Karajannis, P.; Kaustova, J. Synthesis and antimycobacterial activity of salicylanilides substituted in position 5 Chem. Pap. 2001, 55, 121-129
51. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997, 23, 3-25 (Pubitemid 27046991)
52. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 2002, 45, 2615-2623 (Pubitemid 34595232)
53. Rossignol, J.-F. Thiazolides: a new class of antiviral drugs Expert Opin. Drug Metab. Toxicol. 2009, 5 (6) 667-674
54. Stockis, A.; De Bruyn, S.; Gengler, C.; Rosillon, D. Nitazoxanide pharmacokinetics and tolerability in man during 7 days dosing with 0.5 and 1 g b.i.d Int. J. Clin. Pharmacol. Ther. 2002, 40, 221-227 (Pubitemid 34467681)
55. Broekhuysen, J.; Stockis, A.; Lins, R. L.; De Graeve, J.; Rossignol, J.-F. Nitazoxanide: pharmacokinetics and metabolism in man Int. J. Clin. Pharmacol. Ther. 2000, 38, 387-394 (Pubitemid 30650157)
56. Rossignol, J.-F.; Elfert, A.; El-Gohary, Y.; Keeffe, E. B. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin Gastroenterology 2009, 136, 856-862
57. Pipeline Pilot Student Edition. http://accelerys.com/products/scitegic/.
58. Todeschini, R.; Mauri, A.; Pavan, M. DRAGON, Web version 3.0; 2003.
59. Steinbeck, C; Hoppe, C.; Kuhn, S; Floris, M.; Guha, R.; Willighagen, E. L. Recent developments of the Chemistry Development Kit (CDK, version 0.94): an open-source Java library for chemo- and bioinformatics Curr. Pharm. Des. 2006, 12, 2111-2120 (Pubitemid 43891407)
60. Durham, S. K.; Pearl, G. M. Computational methods to predict drug safety liabilities Curr. Opin. Drug Discovery Dev. 2001, 4, 102-109
61. Eriksson, L.; Jaworska, J.; Worth, A. P.; Cronin, M. T.D.; McDowell, R. M. Methods for reliability and uncertainty assessment and for applicability evaluation of classification and regression-based QSARs Environ. Health Perspect. 2003, 111, 1361-1375 (Pubitemid 37021142)
62. Bonchev, D. Information Theoretic Indices for Characterization of Chemical Structures; RSP-Wiley: Chichester, U.K., 1983.
63. Benigni, R.; Passerini, L.; Pino, A.; Giuliani, A. The information content of the eigenvalues from modified adjacency matrices: large scale and small-scale correlations Quant. Struct.-Act. Relat. 1999, 15, 449-455
64. Todeschini, R.; Consonni, V. Handbook of Molecular Descriptors; Wiley-VCH: Weinheim, Germany, 2000.
65. Guidance Document on the Validation of (Quantitative) Structure-Activity Relationships [(Q)SAR] Models, QECD; Paris, 2007; Vol. 69.
66. Ballard, T. E.; Wang, X.; Olekhnovich, I.; Koerner, T.; Seymour, C.; Hoffman, P. S.; Macdonald, T. L. Biological activity of modified and exchanged 2-amino-5-nitrothiaole amide analogues of nitazoxanide Bioorg. Med. Chem. Lett. 2010, 20, 3537-3539
67. Muller, J.; Wastling, J.; Sanderson, S.; Muller, N.; Hemphill, A. A novel Giardia lamblia nitroreductase, G1NR1, interacts with nitazoxanide and other thiazolides Antimicrob. Agents Chemother. 2007, 51, 1979-1986 (Pubitemid 46903083)
68. Rossignol, J.-F.; La Frazia, S.; Chiappa, L.; Ciucci, A.; Santoro, M. G. Thiazolides, a new class of anti-influenza molecules targeting viral haemagglutinin at the post-translational level J. Biol. Chem. 2009, 284, 29798-29808
69. Korba, B. E.; Elazar, M.; Lui, P.; Glenn, J. S.; Rossignol, J.-F. Potential role for nitazoxanide in combination with STAT-C agents for the inhibition of HCV replication without the development of resistance Hepatology 2008, 48 (Suppl.) 356A
70. Latest results, to be published elsewhere; cf. Rossignol, J.-F.; Elfert, A.; Keeffe, E. B. Treatment of chronic hepatitis C using a 4-week lead-in with nitazoxanide before peginterferon plus nitazoxanide J. Clin. Gastroenterol. 2010, 44, 504-509
71. Korba, B. E.; Elazar, M.; Lui, P.; Rossignol, J.-F.; Glenn, J. S. Studies of the potential for nitazoxanide or tizoxanide resistance in hepatitis C virus replicon-containing cell lines Antimicrob. Agents Chemother. 2008, 52, 4069-4071
72. Elazar, M.; Liu, M.; McKenna, S. A.; Liu, P.; Gehrig, E. A.; Puglisi, J. D.; Rossignol, J.-F.; Glenn, J. S. The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2 alpha via protein kinase activated by double-stranded RNA activation Gastroenterology 2009, 137, 1827-1835
73. Trabattoni, D.; Pacei, M.; Biasin, M.; De Luca, C.; Clerici, M.; Rossignol, J.-F. Antimicrobial Nitazoxanide Shows Strong Immunomodulating Effects. Presented at the 98th Annual Meeting of the American Association of Immunologists, San Francisco, CA, May 13-17, 2011.
74. Sells, M. A.; Zelent, A. Z.; Shvartsman, M.; Acs, G. Replicative intermediates of hepatitis B virus in Hep G2 cells that produce infectious virions J. Virol. 1988, 62, 2836-2844
75. Helal, C. J.; Sanner, M. A.; Cooper, C. B.; Gant, T.; Adam, M.; Lucas, J. C.; Kang, Z.; Kupchinsky, S.; Ahlijanian, M. K.; Tate, B.; Menniti, F. S.; Kelly, K.; Peterson, M. Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimers disease Bioorg. Med. Chem. Lett. 2004, 14, 5521-5525 (Pubitemid 39346337)
76. Balon, Ya. G.; Shulman, M. D.; Kuznetsov, N. V. New reactions of aryldichloromethylcarbinols Zh. Org. Khim. 1979, 15, 2351-2356
77. Livingstone, D. J.; Rahr, E. Chorchop - an interactive routine for the dimension reduction of large QSAR data sets Quant. Struct.-Act. Relat. 1989, 8, 103-108 (Pubitemid 19191670)
78. Leach, A. R.; Gillet, V. J. Introduction to Chemoinformatics; Springer: Dordrecht, The Netherlands, 2007.
79. Draper, N. R.; Smith, H. Applied Regression Analysis; John Wiley and Sons,: New York, 1991; http://www.phakiso.com.
80. Eriksson, L.; Jaworska, J.; Worth, A. P.; Cronin, M. T.D.; McDowell, R. M. Methods for reliability and uncertainty assessment and for applicability evaluation of classification and regression-based QSARs Environ. Health Perspect. 2003, 111, 1361-1375 (Pubitemid 37021142)